Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 70

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 70
---
 operating company for the FYARRO Business. Aadi Sub is a corporation organized under the laws of the State
of Delaware.

KAKEN PHARMACEUTICAL CO., LTD. (Kaken Parent)

Kaken Parent develops, produces, and sells pharmaceuticals and agrochemicals. Kaken Parent’s products are mainly for orthopedics and dermatology. Kaken
Parent also manufactures feed additives.

KAKEN INVESTMENTS INC. (Kaken)

Kaken was formed on December 13, 2024, for the purpose of engaging in the transactions contemplated by the Divestiture Agreement. Kaken has not engaged in
any business activities other than as incidental to its formation and in connection with the transactions contemplated by the Divestiture Agreement.

Effects of the Divestiture

On
the terms and subject to the conditions set forth in the Divestiture Agreement, at the completion of the Divestiture, (1) Aadi will sell, assign, transfer, convey and deliver 100% of the issued and outstanding shares of Aadi Sub’s capital
stock (all of which are owned beneficially and of record by Aadi) to Kaken, and (2) Kaken will purchase 100% of the issued and outstanding shares of Aadi Sub’s capital stock from Aadi.

Effect on Aadi if the Divestiture is Not Completed

If the Divestiture Agreement is not approved by our stockholders, or if the Divestiture is not completed for any other reason, Aadi will not receive payment
for its shares of Aadi Sub’s capital stock in connection with the Divestiture. Instead, (1) Aadi Sub will remain a wholly owned subsidiary of Aadi, (2) Aadi will remain the sole owner of capital stock of Aadi Sub, and (3) Aadi
will continue to file periodic reports with the SEC including Aadi Sub. In addition, if the Divestiture is not completed, we expect that: (A) our management will continue to operate the FYARRO Business as it is currently being operated, and
(B) our stockholders will continue to be subject to the same risks and opportunities to which they are currently subject.

- 47 -

Furthermore, if the Divestiture is not completed, and depending on the circumstances that cause the
Divestiture not to be completed, the price of our common stock may decline significantly.

Accordingly, there can be no assurance as to the effect of the
Div